The vulnerable atherosclerotic plaque

Bibliography

• Heart and Stroke Facts. American Heart Association, Dallas, TX (1997).http://207.211.141.25/scientific/hsstats98/index.html
   Google Scholar
• •A useful web site with up-to-date data on heart diseases, statistics and treatment.
   Google Scholar
• SUCKLING KE: Atherosclerosis. Encyclopedia of Human Biology (Second Edition). Academic Press, New York (1997). L.1.555–563.
   Google Scholar
• •A simple introductory overview.
   Google Scholar
• STARY HC, CHANDLER AB, DINSMORE RE, et al.: A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Arterioscler. Thromb. Vasc. Biol. (1995) 15:1512–1531.
   PubMed Web of Science ®Google Scholar
• •An authoritative statement on pathology and clinical manifestations of atherosclerosis.
   Google Scholar
• BROWN BG, ZHAO XQ, SACCO DE, ALBERS JJ: Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease. Ann. Rev. Med. (1993) 44:365–376.
   PubMed Web of Science ®Google Scholar
• •A review of studies of cholesterol lowering with statins monitored by angiography. Early suggestions that statins may have an effect on plaque stability.
   Google Scholar
• HEBERT PR, GAZIANO JM, CHAN-KS, HENNEKENS CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA (1997) 278:313–321.
   PubMed Web of Science ®Google Scholar
• •An up-to-date review of the recent significant trials.
   Google Scholar
• BLAUW GJ, LAGAAY AM, SMELT AHM, WESTENDORP RGJ: Stroke, statins and cholesterol - a meta-analysis of randomized placebo-controlled double-blind trials with HMG-CoA reductase inhibitors. Stroke (1997) 28:946–950.
   PubMed Web of Science ®Google Scholar
• WARLOW C, WARDLAW J: The drug trials that have influenced our clinical practice in acute ischaemic stroke. Thromb. Haemost. (1997) 78:558–561.
   PubMed Web of Science ®Google Scholar
• JUUL-MOLLER S, EDVARDSON N, JAHNMATZ B, et al.: Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) group. Lancet (1992) 340:1421–1425.
   PubMed Web of Science ®Google Scholar
• DAVIES MJ: Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995. Circulation (1996) 94:2013–2020.
   PubMed Web of Science ®Google Scholar
• •An authoritative account by one of the originators of the concept of plaque instability.
   Google Scholar
• FALK E: Morphologic features of unstable atherothrombotic plaques underlying acute coronary syndromes. Am. J. Cardiol. (1989) 63:114E–120E.
   Google Scholar
• STEIN Y: Comparison of European and USA guidelines for prevention of coronary heart disease. Atherosclerosis (1994) 110(Suppl.):S41–S44.
   Google Scholar
• •A summary of the perspectives of expert groups in both continents.
   Google Scholar
• RECKLESS JP: Economic issues in coronary heart disease prevention. Curr. Opin. Lipidol. (1996) 7:356–362.
   PubMed Web of Science ®Google Scholar
• •A considered contribution to the debate about who to treat with drugs that are known to be effective but thought to be expensive.
   Google Scholar
• ROSS R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 362:801–809.
   PubMed Web of Science ®Google Scholar
• •One of the classic papers on pathogenesis of atherosclerosis by one of the most influential figures in the field over several decades. Emphasises cell types and the interactions/communications between cells in the developing lesion, defining many potential targets.
   Google Scholar
• GENG YJ, LIBBY P: Evidence for apoptosis in advanced human atheroma. Co-localization with interleukin-1 beta-converting enzyme. Am. J. Pathol. (1995) 147:251–266.
   PubMed Web of Science ®Google Scholar
• BURKE AP, FARB A, MALCOLM GT, et al.: Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. New Engl. J. Med. (1997) 336:1276–1282.
   PubMed Web of Science ®Google Scholar
• FUSTER V, BADIMON J, CHESEBRO JH, FALLON JT: Plaque rupture, thrombosis and therapeutic implications. Haemostasis (1996) 26 (Suppl. 14) :269–284.
   PubMedGoogle Scholar
• •A useful review of plaque rupture in the context of the clinical manifestations and the drugs that are available.
   Google Scholar
• DAVIES MJ, RICHARDSON PD, WOOLF N, KATZ DR, MANN J: Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br. Heart J. (1993) 69:377–381.
   PubMedGoogle Scholar
• GALIS ZS, SUKHOVA GK, LARK MW, LIBBY P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaque. J. Clin. Invest. (1994) 94:2493–2503.
   PubMed Web of Science ®Google Scholar
• SHANAHAN CM, CARY NR, METCALF JC, WEISSBERG PL: High expression of genes for calcification - regulating proteins in human atherosclerotic plaques. J. Clin. Invest. (1994) 93:2393–2402.
   PubMed Web of Science ®Google Scholar
• LIBBY P, SUKHOVA G, LEE RT, GALIS Z: Cytokines regulate vascular functions related to the stability of the atherosclerotic plaque. J. Cardiovasc. Pharmacol. (1995) 25 (Suppl. 2) :S9–S12.
   PubMed Web of Science ®Google Scholar
• VICTOR BC, HELFANT RH: Do inflammatory cells cause coronary artery plaque rupture or are they recruited to sites after rupture Circulation (1996) 94:1–514.
   PubMed Web of Science ®Google Scholar
• MACH F, SCHONBECK U, SUKHOVA GK, et al.: Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40 - CD40 ligand signaling in atherosclerosis. Proc. Natl. Acad. Sci. USA (1997) 94:1931–1936.
   PubMed Web of Science ®Google Scholar
• KAARTINEN M, PENTTILA A, KOVANEN PT: Mast cells accompany microvessels in human coronary atheromas: implications for intimal neovascularization and hemorrhage. Atherosclerosis (1996) 123:123–131.
   PubMed Web of Science ®Google Scholar
• DAVIES MJ: The role of plaque pathology in coronary thrombosis. Clin. Cardiol. (1997) 20(Suppl. l):I-2, 1–7.
   PubMed Web of Science ®Google Scholar
• •A well-illustrated review of the thrombotic aspects of plaque instability.
   Google Scholar
• HELD PH, YUSUF S: Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur. Heart J. (1993) 14(Suppl. F):18–15.
   PubMed Web of Science ®Google Scholar
• CRUICKSHANK JM: The beta-1 hyperselectivity in beta-blocker treatment. J. Cardiovasc. Pharmacol. (1995) 25 (Suppl. 1):S35–S46.
   PubMed Web of Science ®Google Scholar
• JESPERSEN CM: Anti-ischaemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil. Am. J. Cardiol. (1996) 77:32D–36D.
   Google Scholar
• FURBERG CD, PSATY BM: Should calcium antagonists be first-line agents in the treatment of cardiovascular disease The public health perspective. Cardiovasc. Drugs Ther. (1996) 10:463.
   PubMed Web of Science ®Google Scholar
• KIOWSKI W, SUTSCH G, DOSSEGGER L: Clinical benefit of angiotensin-converting enzyme inhibitors in chronic heart failure. J. Cardiovasc. Pharmacol. (1996) 27\(Suppl. 2):S19–S24.
   PubMed Web of Science ®Google Scholar
• MACH F, SCHONBECK U, BONNEFOY JY, POBER JS, LIBBY P: Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor. Circulation (1997) 96:396–399.
   PubMed Web of Science ®Google Scholar
• DE FEYTER PJ, OZAKI Y, BAPTISTA J, et al.: Ischemia-related lesion characteristics in patients with stable or unstable angina. A study with intracoronary angioscopy and ultrasound. Circulation (1995) 92:1408–1413.
   PubMed Web of Science ®Google Scholar
• WEXLER L, BRUNDAGE B, CROUSE J, et al.: Coronary artery calcification: pathophysiology, epidemiology, imaging methods and clinical implications. A statement for health professionals from the American Heart Association Writing Group. Circulation (1996) 94:1175–1192.
   PubMed Web of Science ®Google Scholar
• TASHIRO H, SHIMO KAWA H, YAMAMOTO K, et al.: Altered plasma levels of cytokines in patients with ischemic heart disease. Coronary Artery Dis. (1997) 8:143–147.
   PubMed Web of Science ®Google Scholar
• SELWYN AP, KINLAY S, LIBBY P, GANZ P: Atherogenic lipids, vascular dysfunction and clinical signs of ischemic heart disease. Circulation (1997) 95:5–7.
   PubMed Web of Science ®Google Scholar
• SUCKLING KE: Anti-atherosclerotic patents following the success of HMG-CoA reductase inhibitors. Exp. Opin. Ther. Patents (1996) 6:427–430.
   Web of Science ®Google Scholar
• DAVIES MJ, GORDON JL, GEARING AJ, et al.: The expression of the adhesion molecules ICAM-1, VCAM-1 PECAM and E-selectin in human atherosclerosis. J. Pathol. (1993) 171:223–229.
   PubMed Web of Science ®Google Scholar
• GALIS ZS, MUSZYNSKI M, SUKHOVAGK, SIMON-MORRISSEY E, LIBBY P: Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesion. Ann. NY Acad. Sci. (1995) 748:501–507.
   PubMed Web of Science ®Google Scholar
• LEE RT, SCHOEN FJ, LOREE HM, LARK MW, LIBBY P: Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arterioscler. Thromb. Vasc. Biol. (1996) 16:1070–1073.
   PubMed Web of Science ®Google Scholar
• SHAH PK, FALK E, BADIMON J, et al.: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation (1995) 92:1565–1569.
   PubMed Web of Science ®Google Scholar
• HENNEY AM, WAKELEY PR, DAVIES MJ, et al.: Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc. Natl. Acad. Sci. USA (1991) 88:8154–8158.
   PubMed Web of Science ®Google Scholar
• BJORKERUD S, BJORKERUD B: Apoptosis is abundant in human atherosclerotic lesion, especially in inflammatory cells (macrophages and T-cells), and may contribute to the accumulation of gruel and plaque instability. Am. J. Pathol. (1996) 149:367–380.
   PubMed Web of Science ®Google Scholar
• GENG YJ, WU Q, MUSZYNSKI M, HANSSON GK, LIBBY P: Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha and interleukin-1 beta. Arterioscler. Thromb. Vasc. Biol. (1996) 16:19–27.
   PubMed Web of Science ®Google Scholar
• FERNANDEZ-ORTIZ A, BADIMON J, FALK E, et al.: Characterisation of the relative thrombogenicity of atherosclerotic plaque components, implications for consequences of plaque rupture. J. Am. Coll. Cardiol. (1994) 23:1562–1569.
   PubMed Web of Science ®Google Scholar
• BARSTAD RM, HAMERS MJ, KIERULF P, WESTVIK AB, SAKARIASSEN KS: Procoagulant human monocytes mediate tissue factor/factor VIIa-dependent platelet-thrombus formation when exposed to flowing non-anticoagulated human blood. Arterioscler. Thromb. Vasc. Biol. (1995) 15:11–16.
   PubMed Web of Science ®Google Scholar
• BLANN AD, MILLER JP, MCCOLLUM CN: von Willebrand Factor and soluble E-selectin in the prediction of cardiovascular disease progression in hyperlipidemia. Atherosclerosis (1997) 132:151–156.
   PubMed Web of Science ®Google Scholar
• TERRES W, TATSIS E, PFALZER B, et al.: Rapid angiographic progression of coronary artery disease in patients with elevated lipoprotein (a). Circulation (1995) 91:948–950.
   PubMed Web of Science ®Google Scholar
• BOSTROM AG, CUPPLES LA, JENNER JL, et al.: Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger: a prospective study. J. Am. Med. Assoc. (1996) 276:544–548.
   Web of Science ®Google Scholar
• LUPU F, BERGONZELLI GE, HEIM DA, et al.: Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler. Thromb. Vasc. Biol. (1993) 13:1090–1100.
   PubMed Web of Science ®Google Scholar
• RUDDOCK V, MEADE TW: Factor-VII activity and ischemic heart disease: fatal and non-fatal events. Quart. J. Med. (1994) 87:403–406.
   Google Scholar
• MERLINI PA, ARDISSINO D, OLTRONA L, et al.: Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes. Arterioscler. Thromb. Vasc. Biol. (1995) 15:1675–1679.
   PubMed Web of Science ®Google Scholar
• DENESH J, COLLINS R, PETO R: Chronic infections and coronary heart disease - is there a link Lancet (1997) 350:430–436.
   PubMed Web of Science ®Google Scholar